American firm Cytiva has announced the launch of X-platform bioreactors to simplify single-use upstream bioprocessing operations. X-platform bioreactors, initially available in 50 and 200 L sizes are provided with Figurate automation solution software and can increase process efficiency through ergonomic improvements, production capability and simplified supply chain operations. The bioreactors also work with the Cytiva Bioreactor Scaler to determine the optimal target settings for scaling without trial and error.
Xcellerex bioreactors were first developed 20 years ago and today thousands of Xcellerex bioreactors are in labs or manufacturing workflows across the world. As well as monoclonal antibodies (mAbs), the X-platform can be used to manufacture cell and gene therapies as well as viral vectors. The majority of mAbs approved by the Food and Drug Administration (FDA) in 2022 use Cytiva technologies in their manufacture.
X-platform bioreactors from Cytiva are designed to meet process needs of today and tomorrow. Starting in 2023, customers can order the 50 or 200 L size X-platform bioreactors (larger sizes are coming in 2024) and see it for themselves at Interphex in New York City from 25 to 27 April 2023, as well as other global events throughout the year.
